Thrombosis Journal最新文献

{"title":"Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism.","authors":"Masashi Yoshida, Kentaro Ejiri, Naoaki Matsuo, Takanori Naito, Kazuhiro Kuroda, Koji Tokioka, Kunihiko Hatanaka, Ryohei Fujimoto, Hidenaru Yamaoka, Yutaka Kajikawa, Kazuki Suruga, Hiroki Sugiyama, Tsuyoshi Miyaji, Yoshimasa Morimoto, Nobuhiro Okamura, Toshihiro Sarashina, Satoshi Akagi, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Ito, Shinsuke Yuasa","doi":"10.1186/s12959-025-00720-0","DOIUrl":"https://doi.org/10.1186/s12959-025-00720-0","url":null,"abstract":"<p><strong>Background: </strong>Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence. In patients with cancer, however, recurrent VTE after DOAC treatment may be more common than in noncancer patients. To evaluate our hypothesis that the anticoagulation effect of edoxaban is lower in VTE patients with cancer than in noncancer patients.</p><p><strong>Methods: </strong>This study was a prospective, multicenter, observational study including patients treated with edoxaban for VTE in Japan. The primary outcome was the difference in the prothrombin time (PT), activated partial thromboplastin time (APTT), and D-dimer level at 5 h after initial edoxaban administration between the cancer and noncancer groups. An additional outcome was the longitudinal change in PT and APTT from 5 h to overnight after edoxaban administration. The incidence of adverse events was further investigated.</p><p><strong>Results: </strong>PT and APTT at 5 h after initial edoxaban administration were not significantly different between the cancer (n = 84) and noncancer groups (n = 138) (e.g., log-transformed APTT 3.55 vs. 3.55, p = 0.45). However, D-dimer in the cancer groups was significantly greater than that in the noncancer groups (log-transformed 1.83 vs. 1.79, p = 0.009). PT and APTT significantly decreased from 5 h to overnight after edoxaban, but a similar pattern was observed in each group. All adverse events after edoxaban administration were also similar between patients with cancer and noncancer.</p><p><strong>Conclusion: </strong>PT and APTT after edoxaban administration were similar between VTE patients with cancer and noncancer groups, suggesting that edoxaban has anticoagulation effects on cancer-associated VTE similar to those of noncancer patients.</p><p><strong>Trial registration: </strong>UMIN000041973; Registration Date: 2020.10.5.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"36"},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tissue factor, factor VIII and IX in microvesicle-induced thrombosis and tumor growth of pancreatic cancer.","authors":"Sheng-Chieh Chou, Shu-Lun Chang, Cheng-Yeh Yu, Chao-I Lin, Yen-Ting Chang, Li-Fu Chen, Jia-Yi Li, Chen-Hsueh Pai, Shu-Rung Lin, Wern-Cherng Cheng, Chang-Tsu Yuan, Shu-Wha Lin","doi":"10.1186/s12959-025-00715-x","DOIUrl":"https://doi.org/10.1186/s12959-025-00715-x","url":null,"abstract":"<p><strong>Background: </strong>Tissue factor (TF)-rich cancer microvesicles are correlated with thrombosis risk. Intrinsic coagulation factors are also associated with the risk of thrombosis in cancer patients. This study explored the roles of pancreatic cancer-derived microvesicles and intrinsic factors in thrombogenesis.</p><p><strong>Methods: </strong>Human pancreatic cancer cell lines rich in TF (AsPC-1-TF^high, MIAPaCa-2-TF^high) or poor in TF [AsPC-1-TF^KO(knockout) and MIAPaCa-2-TF^low] were generated for microvesicle preparation and injected into coagulation-defective mice. Inferior vena cava (IVC) clots and lung thrombosis were evaluated. Immunodeficient hemophilia A (NSG-HA) mice were orthotopically injected with the cells mentioned above, and the tumor and IVC clot weights were analyzed.</p><p><strong>Results: </strong>With the injection of TF^high microvesicles, IVC clots were rarely found in hemophilic mice. The TF^low and TF^KO microvesicles resulted in few IVC clots in any mouse. Lung thrombosis was substantially reduced in the hemophilic mice infused with any microvesicle type. In orthotopic tumor models, TF^high cells grew faster than did TF^low cells. TF^high tumor-bearing NSG-WT mice had the most enormous IVC clots, whereas NSG-HA mice had no IVC clots.</p><p><strong>Conclusion: </strong>Pancreatic cancer thrombosis induced by TF-expressing microvesicles strongly depended on FVIII and FIX, while VWF played a minor role. Moreover, TF, but not FVIII, was significantly related to tumor growth.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"32"},"PeriodicalIF":2.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the risk of postoperative venous thromboembolism in rhinoplasty patients: a cohort study.","authors":"Jie Chen, Jianfei Zhang, Xia Xiao, Yujun Tang, Hejin Huang, Wenwen Xi, Lina Liu, Zhengzhou Shen, Jianhua Tan, Feng Yang","doi":"10.1186/s12959-025-00712-0","DOIUrl":"https://doi.org/10.1186/s12959-025-00712-0","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) is a rare complication following rhinoplasty surgery, with an occurrence rate generally estimated to be between 0.5% and 1%. In contrast, the occurrence rate of VTE in orthopedic surgeries, particularly in lower limb fracture surgeries, can reach as high as 10% or more. This significant difference highlights the varying risks associated with different surgical procedures and underscores the importance of identifying risk factors specific to rhinoplasty. Despite its relatively low incidence, the potential for VTE in rhinoplasty patients necessitates a thorough analysis of risk factors to enhance patient safety and guide clinical practice. This study aims to analyze the risk factors for postoperative VTE in rhinoplasty patients and develop a predictive model to assist clinicians in identifying at-risk individuals.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 1100 rhinoplasty patients admitted to a cosmetic hospital from January 2016 to January 2022. Patients were divided into Non-VTE group (1012 cases) and VTE group (88 cases) based on the occurrence of VTE within one month postoperatively. General patient information was collected and subjected to univariate analysis. Multivariate logistic regression analysis was used to identify risk factors for postoperative VTE in rhinoplasty patients and establish a predictive model. Internal validation was performed using bootstrapping technique to assess the accuracy and predictive performance of the model.</p><p><strong>Results: </strong>Univariate analysis showed that the proportions of IBD, Myocardial infarction, Previous VTE, PICC/central line, Rib graft, and History of nasal surgery were significantly higher in the VTE group compared to the Non-VTE group (all P < 0.05). Multivariate logistic regression analysis identified IBD, Myocardial infarction, Previous VTE, Rib graft, and History of nasal surgery as independent risk factors for VTE (P < 0.05). The constructed predictive nomogram model demonstrated good calibration and predictive accuracy, with an area under the ROC curve of 0.845, indicating excellent discrimination and clinical predictive performance.</p><p><strong>Conclusion: </strong>IBD, Myocardial infarction, Previous VTE, Rib graft, and History of nasal surgery are independent risk factors for postoperative VTE in rhinoplasty patients. The predictive model effectively assesses the risk of VTE in patients, providing important guidance for clinical decision-making.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"33"},"PeriodicalIF":2.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thromboelastography-based dynamic evaluation of perioperative coagulation changes and anticoagulant efficacy in lung cancer patients.","authors":"Songping Cui, Ruiheng Jiang, Jiaojie Zhao, Jing Wang, Bin Hu, Hui Li, Shuo Chen","doi":"10.1186/s12959-025-00718-8","DOIUrl":"https://doi.org/10.1186/s12959-025-00718-8","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) is a common postoperative complication in oncologic surgery, closely associated with perioperative hypercoagulability. Thromboelastography (TEG) may be an effective method for monitoring hypercoagulability and guiding preventive anticoagulation.</p><p><strong>Methods: </strong>We prospectively collected perioperative clinical data from lung cancer surgery patients at our hospital between June 2019 and January 2020. TEG and coagulation-related indicators were monitored preoperatively, and on postoperative days 1 and 3. Newly diagnosed postoperative VTE was monitored using lower limb color doppler ultrasound.</p><p><strong>Results: </strong>A total of 241 lung cancer surgery patients were included, with 25 developing VTE postoperatively (10.4%). TEG results showed a significant decrease in the R value (a thrombin marker) on postoperative day 1, followed by an increase on day 3. The MA value (a platelet marker) increased postoperatively. D-dimer levels also rose after surgery. On postoperative day 1, thrombin-related hypercoagulability was predominant (15/17 preoperatively, 40/46 postoperatively), whereas platelet-related hypercoagulability was dominant on postoperative day 3 (18/35). Patients who received prophylactic anticoagulation had significantly higher R values on day 3. The ROC curve for D-dimer predicting new-onset VTE showed AUCs of 0.732, 0.790, and 0.847 preoperatively, on days 1, and 3, respectively.</p><p><strong>Conclusion: </strong>D-dimer helps identify high-risk patients for postoperative VTE, while TEG aids in classifying and monitoring hypercoagulability, optimizing anticoagulation therapy choices and dosages.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"31"},"PeriodicalIF":2.6,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of combined oral contraceptives on thrombin generation assessed on ST Genesia- a paired clinical study.","authors":"Jesper Strandberg, Inger Lise Gade, Jette Nybo, Janus Nikolaj Laust Thomsen, Søren Risom Kristensen","doi":"10.1186/s12959-025-00713-z","DOIUrl":"10.1186/s12959-025-00713-z","url":null,"abstract":"<p><strong>Background: </strong>Treatment with combined oral contraceptives (COC) is associated with an increased risk of venous thromboembolism. Several changes of coagulant and anticoagulant factors induced by ethinyloestradiol during treatment with COC, have been demonstrated. Thrombin generation is a global test measuring both coagulant and anticoagulant factors, but the effect of COC on individuals starting COC, has not been examined before on the new equipment, ST Genesia. The aim of this project was to examine the effect of COC on thrombin generation on ST Genesia, in individuals before and after starting COC.</p><p><strong>Methods: </strong>Twenty-four female participants between 15 and 34 years of age, who were about to start treatment with ethinylestradiol/levonorgestrel-containing COC, were included in the study. Two blood samples were drawn from each of the study subjects, a baseline sample immediately before first COC dose, and a follow-up blood sample approximately 3-4 months after COC start. Standard biochemical analyses as well as standard and special coagulation analyses including thrombin generation on ST Genesia, were performed in all samples.</p><p><strong>Results: </strong>Thrombin generation, i.e., endogenous thrombin generation (ETP) and peak increased considerably after COC start, whereas time-to-peak was shortened. Thrombin-antithrombin complexes (TAT), prothrombin fragments (F1 + 2) and sex hormone binding globulin (SHBG) increased, and the coagulation inhibitors tissue factor pathway inhibitor (TFPI), protein S activity and antithrombin decreased slightly after COC start.</p><p><strong>Conclusion: </strong>Although the coagulation factors only changed modestly, the global test thrombin generation performed on ST Genesia showed a considerable change after start of COC.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"30"},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11978137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of MTHFR missense variants with thromboembolic diseases and coagulation factor levels in European populations.","authors":"Iyas Daghlas, Mengmeng Wang, Dipender Gill","doi":"10.1186/s12959-025-00711-1","DOIUrl":"10.1186/s12959-025-00711-1","url":null,"abstract":"<p><strong>Background: </strong>Investigations of the association between missense variants in the methylenetetrahydrofolate reductase (MTHFR) gene and thromboembolic diseases have been limited by small sample sizes. The effect of these variants on coagulation factor levels remains similarly uncertain.</p><p><strong>Objectives: </strong>To test the association of the C677T and A1298C missense variants in MTHFR with risk of venous thromboembolism (VTE), cardioembolic stroke (CES), and circulating coagulation cascade protein levels.</p><p><strong>Patients/methods: </strong>We analyzed genetic associations of MTHFR missense variants with VTE (81,190 cases and 1,419,671 controls), CES (10,804 cases and 1,234,808 controls), and circulating levels of coagulation cascade proteins from the deCODE (n = 35,559) and UK Biobank (n = 46,218) cohorts. All participants in these genetic analyses were of European ancestry. We report odds ratios (OR) and beta coefficients per copy of the missense variant. VTE associations were compared to the effect of the Factor V Leiden variant.</p><p><strong>Results: </strong>The A1298C variant conferred a small increased risk of VTE (OR per allele: 1.03, 95% confidence interval [CI] 1.02-1.04, P = 1.36 × 10^- 6). This effect was 30-fold weaker than the effect of Factor V Leiden on VTE. After correction for multiple comparisons, the C677T variant did not demonstrate a significant association with VTE (OR 0.99, 95% CI 0.98-1.00, P = 0.04). Neither variant was associated with CES (P ≥ 0.18), nor with any of the 34 coagulation cascade proteins after correction for multiple comparisons.</p><p><strong>Conclusions: </strong>These data do not support a role for MTHFR genetic testing as part of an inherited thrombophilia evaluation.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"29"},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11978176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A mendelian randomization study on the association between 731 types of immune cells and 91 types of blood cells with venous thromboembolism.","authors":"Yue Zhang, Rui Wang","doi":"10.1186/s12959-025-00714-y","DOIUrl":"10.1186/s12959-025-00714-y","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) is a grave medical condition characterized by the blockage of distant blood vessels due to blood clots or detached vessel wall fragments, leading to ischemia or necrosis of the affected tissues. With the recent introduction of immunothrombosis, the significance of immune cells in the process of thrombus formation has gained prominent attention. Complex cross-talk occurs between immune cells and blood cells during infection or inflammation, with immune cells actively participating in blood clot formation by promoting platelet recruitment and thrombin activation. Nevertheless, comprehensive studies on the genetic association between immune cells phenotypes and VTE remain scarce. This article employed Mendelian randomization (MR) to investigate the association between the incidence of VTE and a range of 731 immune cell types, along with 91 blood cell perturbation phenotypes, utilizing single nucleotide polymorphisms as instrumental variables.</p><p><strong>Methods: </strong>Through the utilization of publicly available genetic data, a two-sample bi-directional MR analysis was conducted. Sensitivity analyses included Cochran's Q test, MR-Egger intercept test, MR-pleiotropy residual sum and outlier (MR-PRESSO) and leave-one-out analysis. For significant associations, replication analysis was conducted using GWAS data from deep vein thrombosis (DVT) and pulmonary embolism (PE).</p><p><strong>Results: </strong>We firstly investigated the causal relationship between 731 immune cells and VTE risk. All the GWAS data were obtained from European populations and from men and women. The IVW analysis revealed that CD20 on naive-mature B cell, CD20 on IgD- CD38dim B cell, and CD20 on unswitched memory B cell may increase the risk of VTE (P < 0.05). CD28- CD8dim T cell %T cell, CD64 on monocyte and CD64 on CD14 + CD16- monocyte may be protective factors against DVT (P < 0.05). Then disturbed blood cells types as exposure were analyzed to examine its association with occurrence of VTE. Initial and replication analysis both revealed that environmental KCl-impacted red blood cells and butyric acid-impacted platelet accelerated incidence of VTE (P < 0.05), while colchicine -impacted eosinophil, KCl-impacted reticulocyte and Lipopolysaccharide (LPS) -impacted neutrophil reduced VTE risk (P < 0.05). Sensitivity analyses confirmed the robustness and reliability of these positive findings.</p><p><strong>Conclusions: </strong>Our study presents evidence of a causal link between six immune cell phenotypes and VTE. Additionally, we have identified two types of blood cells that are associated with both VTE and DVT, and three types of blood cells that are relevant to both VTE and PE.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"28"},"PeriodicalIF":2.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of atorvastatin on inflammation and coagulation markers in high-risk thrombotic cancer patients undergoing chemotherapy: a randomized controlled trial.","authors":"Budi Setiawan, Widi Budianto, Tri Wahyu Sukarnowati, Daniel Rizky, Eko Adhi Pangarsa, Damai Santosa, Aru Wisaksono Sudoyo, Tri Indah Winarni, Ignatius Riwanto, Rahajuningsih Dharma Setiabudy, Catharina Suharti","doi":"10.1186/s12959-025-00705-z","DOIUrl":"10.1186/s12959-025-00705-z","url":null,"abstract":"<p><strong>Background: </strong>Deep vein thrombosis (DVT) is a prevalent complication associated with malignancy. Clinical use of thromboprophylaxis is recommended, however its usage is limited due to bleeding complications, more cost associated, and reluctance to receive anticoagulant injections. Rivaroxaban a relatively easy to administer anticoagulant but it has a risk of bleeding and is expensive. Inflammation is the important factor in pathogenesis of cancer-associated thrombosis. Statins have the anti-inflammatory property that could decrease proinflammatory cytokines. Consequently, statins may be used as thromboprophylaxis for cancer patients receiving chemotherapy.</p><p><strong>Objective: </strong>To provide comparison between atorvastatin and rivaroxaban on affecting inflammatory biomarkers (interleukin 6 [IL-6], C reactive protein [CRP]) and coagulation activation biomarkers (Tissue Factor [TF], prothrombin fragment 1 + 2 [F1 + 2], D-Dimer) in cancer patients at high risk of thrombosis receiving chemotherapy.</p><p><strong>Methods: </strong>A randomized controlled study that was double-blinded and involved high-risk cancer patients undergoing chemotherapy. For up to ninety days, participants were randomized to receiver either atorvastatin 20 mg or rivaroxaban 10 mg daily. The level of plasma of IL-6, CRP, TF, F1 + 2, and D-dimer were assessed 24 h before chemotherapy, 30, 60, and 90 day after chemotherapy. The latest observation carried forward (LOCF) approach was used to examine the data. The laboratory results were evaluated using an independent T test or Mann-Whitney U test prior to and after chemotherapy.</p><p><strong>Results: </strong>Eighty-six randomized patients were enrolled, although both groups showed a decreasing trend in plasma level of IL-6, CRP, TF, F1 + 2, and D-dimer, there were no significant differences between the two groups (p > 0.05). In the atorvastatin group, there was a significant correlation between delta level of IL-6 and F1 + 2 (r = 0.313, p = 0.043) and delta level of CRP and F1 + 2 (r = 0.398, p = 0.009), whereas in the rivaroxaban group there was a significant correlation between delta CRP and D-dimer level (r = 0.387, p = 0.009).</p><p><strong>Conclusion: </strong>Atorvastatin decreases IL-6 and CRP level, which also decreases F1 + 2 level. Atorvastatin did not substantially differ from rivaroxaban in decreasing plasma levels of inflammatory biomarkers IL-6, CRP, and coagulation activation biomarkers TF, F1 + 2, D-dimer in high-risk cancer patients undergoing chemotherapy.</p><p><strong>Trial registration: </strong>ISRCTN71891829, Registration Date: 17/12/2020.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"27"},"PeriodicalIF":2.6,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oroxylin A reverses SHP-2 oxidative inactivation in GPVI signaling to suppress platelet activation and thrombus formation.","authors":"Yufei Chen, Yuan Lin, Jin Hong, Jiaorui Wang, Biling Li, Zixian Liu, Yongbo Ma, Xiaolan Sun, Shufang Wang, Mingjie Li, Meiling Wu, Deyu Fu, Jian Li, Mingzhu Wang, Liang Hu","doi":"10.1186/s12959-025-00709-9","DOIUrl":"10.1186/s12959-025-00709-9","url":null,"abstract":"<p><strong>Background: </strong>Arterial thrombotic events are the leading causes of death worldwide, and the therapeutic effects of current antiplatelet drugs are not fully satisfactory. Oroxylin A (OroA), a flavone compound extracted from Scutellaria radix, possesses cardioprotective and many other pharmacological effects. While platelets play a crucial role in the development of myocardial infarction, the direct effects of OroA on platelet activation and thrombosis have yet to be investigated.</p><p><strong>Methods: </strong>FeCl₃-induced arteriole thrombosis and whole-blood perfusion were used to assess the inhibitory effect of OroA on thrombus formation. A myocardial ischemia model was employed to evaluate the protective effect of OroA on myocardial injury. Multiple platelet function studies including platelet aggregation, platelet spreading, clot retraction were performed. Network pharmacology, flow cytometry, enzyme-linked immunosorbent assay, co-immunoprecipitation and western blot were utilized to explore the mechanism of OroA on platelet activation.</p><p><strong>Results: </strong>OroA inhibited thrombus formation with less bleeding risk compared with aspirin. OroA protected against myocardial injury by suppressing microvascular thrombosis and platelet infiltration. OroA suppressed different agonist-induced platelet activation in a concentration-dependent manner, showing greater antiplatelet activity against collagen-induced platelet aggregation compared to ADP or thrombin-induced aggregation. OroA decreased granule release, integrin αIIbβ3 activation, platelet spreading and clot retraction. As a flavone, OroA boosted superoxide dismutase (SOD) and glutathione (GSH) activities and decreased malondialdehyde (MDA), oxidized glutathione (GSSG) and ROS levels in platelets during oxidative stress. OroA binds to SHP-2 and prevents its oxidative inactivation, leading to the tyrosine dephosphorylation of Src, Syk and PLCγ2, as well as the reduction of Ca²⁺ influx and PKC phosphorylation in GPVI signaling.</p><p><strong>Conclusions: </strong>OroA inhibits platelet activation, thrombus formation and myocardial injury via reversing SHP-2 oxidative inactivation thereby attenuating collagen-induced GPVI signaling. With minor bleeding risk and no obvious pharmacological toxicity, OroA holds promising therapeutic potential as an antithrombotic drug.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"26"},"PeriodicalIF":2.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with thrombosis among solid organ cancer patients in Kuala Lumpur, Malaysia.","authors":"Lailatulema Abbas, Ibtisam Muhamad Nor, Fuad Ismail, Sivakumar Palaniappan, Guang Yong Chong, Sharifa Ezat Wan Puteh, Siti Afiqah Muhamad Jamil, Nor Rafeah Tumian","doi":"10.1186/s12959-025-00710-2","DOIUrl":"10.1186/s12959-025-00710-2","url":null,"abstract":"<p><strong>Background: </strong>Patients with solid organ cancers are at increased risk of developing cancer-associated thrombosis (CAT), a complication driven by a complex interplay of patient-specific factors, cancer characteristics, and treatment modalities. Data on CAT and its associated risk factors within diverse ethnic groups, such as the Malaysian population, remains limited. This observational, cohort study aimed to address this gap by determining the incidence of CAT and identifying associated risk factors among multi-ethnic Malaysian patients with solid organ cancers.</p><p><strong>Methods: </strong>This study included solid organ cancer patients aged ≥ 18 who attended HCTM and HKL from May 2022 to August 2023. The baseline demographics, and clinical characteristics, were acquired at the cancer diagnosis. Data on cancer treatment, thrombotic events and anticoagulation therapy during the study and its treatment were documented. Multivariable logistic regression analysis was performed to determine the independent factors associated with CAT in solid organ cancer.</p><p><strong>Results: </strong>A total of 250 solid organ cancer patients were included, with a mean age of 57.7 (13.7) years. This multi-ethnic cohort consisted of mostly Malay patients (55.2%), followed by Chinese (33.2%) and Indian & others (11.6%). The prevalence of CAT at baseline was 4.8%, while the incidence of CAT during follow-up was 12%. Poor performance status and obesity were associated with CAT at baseline. Univariable logistic regression showed platelets ≥ 450 × 10⁹/L and Khorana score ≥ 3 had significantly higher risks of CAT at baseline. Stage IV disease, radiotherapy and chemotherapy, namely platinum-based chemotherapy and antimetabolites were associated with CAT during follow-up. The ROC analysis showed that the KRS significantly predicted CAT (area under the curve, 0.701 (95%CI: 0.594-0.808, p = 0.001).</p><p><strong>Conclusions: </strong>This study highlights the prevalence of CAT at baseline and the incidence of CAT during follow-up, similar to other studies. Patients' clinical characteristics were associated with CAT at baseline while disease and treatment factors were associated with CAT at follow-up. These findings emphasise the need for targeted thromboprophylaxis in high-risk populations and highlight the importance of risk stratification tools such as the Khorana score for optimal patient management. Future studies involving larger patient cohorts and longer study duration would be beneficial. These findings provide valuable insights to inform clinical decision-making, optimise patient outcomes, and minimise potential risks.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"25"},"PeriodicalIF":2.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}